Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

NCT00454298 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis

Interventions

DRUG: AGG-523 (Aggrecanase Inhibitor)

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer